Ignite Creation Date:
2024-07-17 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06475755
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-26
First Post:
2024-05-28
Brief Title:
NeoadjuvantAdjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC
Sponsor:
Tang-Du Hospital
Organization:
Tang-Du Hospital
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-06-30
Start Date Type:
ESTIMATED
Primary Completion Date:
2025-06-10
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2024-05-28
First Submit QC Date:
None
Study First Post Date:
2024-06-26
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-06-20
Last Update Post Date:
2024-06-26
Last Update Post Date Type:
ACTUAL